JP2005500362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005500362A5 JP2005500362A5 JP2003518482A JP2003518482A JP2005500362A5 JP 2005500362 A5 JP2005500362 A5 JP 2005500362A5 JP 2003518482 A JP2003518482 A JP 2003518482A JP 2003518482 A JP2003518482 A JP 2003518482A JP 2005500362 A5 JP2005500362 A5 JP 2005500362A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- water
- active substance
- solid particles
- pharmacologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims description 39
- 239000002245 particle Substances 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 25
- 239000007787 solid Substances 0.000 claims description 21
- 239000013543 active substance Substances 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 239000006185 dispersion Substances 0.000 claims description 20
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 16
- 239000000194 fatty acid Substances 0.000 claims description 16
- 229930195729 fatty acid Natural products 0.000 claims description 16
- -1 fatty acid esters Chemical class 0.000 claims description 13
- 150000004665 fatty acids Chemical class 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000003381 stabilizer Substances 0.000 claims description 9
- 150000003904 phospholipids Chemical class 0.000 claims description 8
- 239000008346 aqueous phase Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000012736 aqueous medium Substances 0.000 claims description 5
- 239000002270 dispersing agent Substances 0.000 claims description 5
- 150000002894 organic compounds Chemical class 0.000 claims description 5
- 150000002009 diols Chemical class 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 3
- 150000005690 diesters Chemical class 0.000 claims description 3
- 150000002191 fatty alcohols Chemical class 0.000 claims description 3
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000012071 phase Substances 0.000 claims 3
- 150000003626 triacylglycerols Chemical class 0.000 claims 3
- 230000001376 precipitating effect Effects 0.000 claims 2
- 238000001016 Ostwald ripening Methods 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 150000001298 alcohols Chemical class 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000001993 wax Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 4
- 150000004668 long chain fatty acids Chemical class 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000005968 1-Decanol Substances 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940113088 dimethylacetamide Drugs 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001304 Solutol HS 15 Polymers 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- PWEOPMBMTXREGV-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O PWEOPMBMTXREGV-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000012169 petroleum derived wax Substances 0.000 description 1
- 235000019381 petroleum wax Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0119081.8 | 2001-08-06 | ||
| GB0119081A GB0119081D0 (en) | 2001-08-06 | 2001-08-06 | Process |
| GB0212463A GB0212463D0 (en) | 2002-05-30 | 2002-05-30 | Process |
| GB0212463.4 | 2002-05-30 | ||
| PCT/GB2002/003583 WO2003013472A1 (en) | 2001-08-06 | 2002-08-01 | Aqueous dispersion comprising stable nanoparticles of a water-insoluble active and an excipient like middle chain triglycerides (mct) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005500362A JP2005500362A (ja) | 2005-01-06 |
| JP2005500362A5 true JP2005500362A5 (https=) | 2006-01-12 |
| JP4714412B2 JP4714412B2 (ja) | 2011-06-29 |
Family
ID=26246405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003518482A Expired - Fee Related JP4714412B2 (ja) | 2001-08-06 | 2002-08-01 | 水不溶性の活性でかつ賦形剤様の中鎖トリグリセリド（ｍｃｔ）の安定なナノ粒子を含む水性分散液 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20050009908A1 (https=) |
| EP (1) | EP1416917B1 (https=) |
| JP (1) | JP4714412B2 (https=) |
| KR (1) | KR100914113B1 (https=) |
| CN (1) | CN1254233C (https=) |
| AT (1) | ATE365537T1 (https=) |
| AU (1) | AU2002317409B2 (https=) |
| BR (1) | BR0211705A (https=) |
| CA (1) | CA2456180C (https=) |
| CY (1) | CY1107059T1 (https=) |
| DE (1) | DE60220923T2 (https=) |
| DK (1) | DK1416917T3 (https=) |
| ES (1) | ES2287293T3 (https=) |
| IL (2) | IL160103A0 (https=) |
| MX (1) | MXPA04001071A (https=) |
| NO (1) | NO20040484L (https=) |
| NZ (1) | NZ530916A (https=) |
| PT (1) | PT1416917E (https=) |
| WO (1) | WO2003013472A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| GB0216700D0 (en) * | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
| GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| GB0230087D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| GB0302671D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| GB0302672D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| GB0302673D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| EP1641779A1 (en) * | 2003-06-18 | 2006-04-05 | AstraZeneca AB | 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator. |
| GB0314057D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314261D0 (en) * | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| WO2006069098A1 (en) * | 2004-12-22 | 2006-06-29 | Elan Pharma International Ltd. | Nanoparticulate bicalutamide formulations |
| US20080193534A1 (en) * | 2005-08-12 | 2008-08-14 | Astrazeneca Ab | Process |
| EP2054036B1 (en) | 2006-07-24 | 2019-12-18 | Singh-Broemer and Company, Inc. | Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening |
| US20100260691A1 (en) * | 2006-07-31 | 2010-10-14 | Narayanan Kolazi S | Aqueous compositions containing a hydrophobic material |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| WO2008097165A1 (en) * | 2007-02-09 | 2008-08-14 | Astrazeneca Ab | Process for preparation of a stable dispersion of solid amorphous submicron particles in an aqueous medium |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| EP2178893A4 (en) * | 2007-07-16 | 2012-09-19 | Poniard Pharmaceuticals Inc | ORAL FORMULATIONS FOR PICOPLATIN |
| WO2009099649A1 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Use of picoplatin and bevacizumab to treat colorectal cancer |
| BRPI1004808B1 (pt) * | 2010-10-27 | 2020-09-29 | Embrapa - Empresa Brasileira De Pesquisa Agropecuária | Composições baseadas em nanopartículas de própolis, processos de obtenção e uso |
| CN107596518B (zh) | 2012-02-29 | 2021-04-23 | 普马特里克斯营业公司 | 可吸入干粉剂 |
| KR102045732B1 (ko) * | 2012-12-28 | 2019-11-18 | 엘지디스플레이 주식회사 | 온도감응형 계면활성제를 이용한 수용성 나노입자의 제조방법 |
| PT106738B (pt) * | 2013-01-09 | 2015-06-08 | Hovione Farmaciencia Sa | Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico |
| EP2954009A1 (de) * | 2013-02-08 | 2015-12-16 | Basf Se | Herstellung von anorganisch-organischen kompositmaterialien durch reaktive sprühtrocknung |
| WO2019055525A1 (en) * | 2017-09-12 | 2019-03-21 | Raj Selvaraj | FORMULATION OF SOLID NANOPARTICLES OF WATER-INSOLUBLE PHARMACEUTICAL SUBSTANCES WITH REDUCED OSTWALD CURING |
| IL312564A (en) | 2021-11-05 | 2024-07-01 | Cinclus Pharma Holding Ab Publ | Polymorphs of the hydrochloride salt of linfarezan glurate |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2224133B2 (de) * | 1972-05-17 | 1974-06-20 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verwendung von bestimmten Mikroorganismen-Stämmen zur Gewinnung von Cholesterinoxydase, welche Cholesterin mit O tief 2 zu Cholestenon + H tief 2 O tief 2 oxydiert |
| US4348385A (en) * | 1980-11-17 | 1982-09-07 | Mobay Chemical Corporation | Flowable pesticides |
| US4610868A (en) * | 1984-03-20 | 1986-09-09 | The Liposome Company, Inc. | Lipid matrix carriers for use in drug delivery systems |
| US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| FR2608988B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
| US4799962A (en) * | 1987-12-24 | 1989-01-24 | Aqualon Company | Water-soluble polymer dispersion |
| US5145648A (en) * | 1988-06-28 | 1992-09-08 | Matsushita Electric Industrial Co., Ltd. | Exhaust smoke purifier apparatus |
| FR2651680B1 (fr) * | 1989-09-14 | 1991-12-27 | Medgenix Group Sa | Nouveau procede de preparation de microparticules lipidiques. |
| DE69112917T2 (de) * | 1990-06-15 | 1996-05-15 | Merck & Co Inc | Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse. |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| CA2125282C (en) * | 1991-12-05 | 1999-08-31 | Jens-Christian Wunderlich | Pharmaceutically applicable nanosol and process for preparing the same |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5468604A (en) * | 1992-11-18 | 1995-11-21 | Eastman Kodak Company | Photographic dispersion |
| GB9319129D0 (en) * | 1993-09-15 | 1993-11-03 | Dowelanco Ltd | Storage and dilution of stable aqueous dispersions |
| SE9303281D0 (sv) * | 1993-10-07 | 1993-10-07 | Astra Ab | New formulation |
| SE9403846D0 (sv) * | 1994-11-09 | 1994-11-09 | Univ Ohio State Res Found | Small particle formation |
| DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| US5665331A (en) * | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| DE69727244T2 (de) * | 1996-10-03 | 2004-11-25 | Hermes Biosciences Inc., San Francisco | Hydrophile Mikroteilchen und Verfahren zu deren Herstellung |
| FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| US6267989B1 (en) * | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6869617B2 (en) * | 2000-12-22 | 2005-03-22 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
| US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
| GB0216700D0 (en) * | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
| GB0302671D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| GB0302673D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| GB0302672D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
-
2002
- 2002-08-01 CN CNB028197941A patent/CN1254233C/zh not_active Expired - Fee Related
- 2002-08-01 IL IL16010302A patent/IL160103A0/xx active IP Right Grant
- 2002-08-01 AT AT02745697T patent/ATE365537T1/de active
- 2002-08-01 DK DK02745697T patent/DK1416917T3/da active
- 2002-08-01 US US10/486,211 patent/US20050009908A1/en not_active Abandoned
- 2002-08-01 AU AU2002317409A patent/AU2002317409B2/en not_active Ceased
- 2002-08-01 CA CA2456180A patent/CA2456180C/en not_active Expired - Fee Related
- 2002-08-01 NZ NZ530916A patent/NZ530916A/en not_active IP Right Cessation
- 2002-08-01 PT PT02745697T patent/PT1416917E/pt unknown
- 2002-08-01 MX MXPA04001071A patent/MXPA04001071A/es active IP Right Grant
- 2002-08-01 DE DE60220923T patent/DE60220923T2/de not_active Expired - Lifetime
- 2002-08-01 ES ES02745697T patent/ES2287293T3/es not_active Expired - Lifetime
- 2002-08-01 EP EP02745697A patent/EP1416917B1/en not_active Expired - Lifetime
- 2002-08-01 JP JP2003518482A patent/JP4714412B2/ja not_active Expired - Fee Related
- 2002-08-01 KR KR1020047001779A patent/KR100914113B1/ko not_active Expired - Fee Related
- 2002-08-01 WO PCT/GB2002/003583 patent/WO2003013472A1/en not_active Ceased
- 2002-08-01 BR BR0211705-3A patent/BR0211705A/pt not_active IP Right Cessation
-
2004
- 2004-01-28 IL IL160103A patent/IL160103A/en not_active IP Right Cessation
- 2004-02-03 NO NO20040484A patent/NO20040484L/no not_active Application Discontinuation
-
2007
- 2007-08-28 CY CY20071101106T patent/CY1107059T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005500362A5 (https=) | ||
| JP4714412B2 (ja) | 水不溶性の活性でかつ賦形剤様の中鎖トリグリセリド（ｍｃｔ）の安定なナノ粒子を含む水性分散液 | |
| Vimalson | Techniques to enhance solubility of hydrophobic drugs: an overview | |
| US7799860B2 (en) | Composition improved in the solubility or oral absorbability | |
| US6368620B2 (en) | Formulations comprising lipid-regulating agents | |
| US6589557B2 (en) | Porous celecoxib matrices and methods of manufacture thereof | |
| CA2076010C (fr) | Microspheres, leur procede de preparation et leur utilisation | |
| US6800297B2 (en) | Porous COX-2 inhibitor matrices and methods of manufacture thereof | |
| KR100669497B1 (ko) | 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법 | |
| FR2918277A1 (fr) | Nouveau procede de production de formes pharmeceutiques seches hydrodispersibles et les compositions hydrodispersibles ainsi obtenues | |
| US20110311625A1 (en) | Solid dosage forms of fenofibrate | |
| JP2017516792A (ja) | 経口イソトレチノイン医薬組成物 | |
| KR100783286B1 (ko) | 클로피도그렐 우선성 광학이성체의 유리염기를 함유하는고형의 약제학적 조성물 | |
| US20080193534A1 (en) | Process | |
| JP2002515415A (ja) | シクロスポリン製剤 | |
| WO2001051029A1 (fr) | Composition d'itraconazole et procede de preparation | |
| US20100068287A1 (en) | Process for Preparation of a Stable Dispersion of Solid Amorphous Submicron Particles in an Aqueous Medium | |
| WO2018225085A1 (en) | Stable solid dispersions of eliglustat hemitartrate | |
| HK1037128A (en) | Non-crystalline solid dispersant comprising cefuromixe axetil | |
| HK1120437A (en) | Pharmaceutical formulation with high stability and dissolution and manufacturing process |